MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/1878-0261.12861

Медицинская библиотека · Molecular oncology · 2020

Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer.

Aguado Cristina, Teixido Cristina, Román Ruth, Reyes Roxana, Giménez-Capitán Ana, Marin Elba, Cabrera Carlos, Viñolas Nuria, Castillo Sergi, Muñoz Silvia, Arcocha Ainara, López-Vilaró Laura, Sullivan Ivana, Aldeguer Erika, Rodríguez Sonia, Moya Irene, Viteri Santiago, Cardona Andrés Felipe, Palmero Ramon, Sainz Cristina, Mesa-Guzmán Miguel, Lozano Maria D, Aguilar-Hernández Andrés, Martínez-Bueno Alejandro, González-Cao María, Gonzalvo Elena, Leenders William P J, Rosell Rafael, Montuenga Luis M, Prat Aleix, Molina-Vila Miguel A, Reguart Noemi

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

MET inhibitors have shown activity in non-small-cell lung cancer patients (NSCLC) with MET amplification and exon 14 skipping (METΔex14). However, patient stratification is imperfect, and thus, response rates have varied widely. Here, we studied MET alterations in 474 advanced NSCLC patients by nCounter, an RNA-based technique, together with next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and reverse transcriptase polymerase chain reaction (RT-PCR), exploring correlation with clinical benefit. Of the 474 samples analyzed, 422 (89%) yielded valid results by nCounter, which identified 13 patients (3%) with METΔex14 and 15 patients (3.5%) with very-high MET mRNA expression. These two subgroups were mutually exclusive, displayed distinct phenotypes and did not generally coexist with other drivers. For METΔex14, 3/8 (37.5%) samples positive by nCounter tested negative by NGS. Regarding patients with very-high MET mRNA, 92% had MET amplification by FISH and/or NGS. However, FISH failed to identify three patients (30%) with very-high MET RNA expression, among which one received MET tyrosine kinase inhibitor treatment deriving clinical benefit. Our results indicate that quantitative mRNA-based techniques can improve the selection of patients for MET-targeted therapies.

Для цитирования: Aguado Cristina, Teixido Cristina, Román Ruth, Reyes Roxana, Giménez-Capitán Ana, Marin Elba, Cabrera Carlos, Viñolas Nuria, Castillo Sergi, Muñoz Silvia, Arcocha Ainara, López-Vilaró Laura, Sullivan Ivana, Aldeguer Erika, Rodríguez Sonia, Moya Irene, Viteri Santiago, Cardona Andrés Felipe, Palmero Ramon, Sainz Cristina, Mesa-Guzmán Miguel, Lozano Maria D, Aguilar-Hernández Andrés, Martínez-Bueno Alejandro, González-Cao María, Gonzalvo Elena, Leenders William P J, Rosell Rafael, Montuenga Luis M, Prat Aleix, Molina-Vila Miguel A, Reguart Noemi. Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer.. Molecular oncology. 2020. DOI: 10.1002/1878-0261.12861.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.